ActiveMax® Recombinant Mouse VEGF164 (HPLC-verified) protein, 50µg

Background
Vascular endothelial growth factor A (VEGFA) is also known as Vascular permeability factor (VPF). VEGFA belongs to the PDGF/VEGF growth factor family. VEGFA is a glycosylated mitogen that specifically acts on endothelial cells and has various effects, including mediating increased vascular permeability, inducing angiogenesis, vasculogenesis and endothelial cell growth, promoting cell migration, and inhibiting apoptosis. Alternatively spliced transcript variants, encoding either freely secreted or cell-associated isoforms, have been characterized. VEGFA is produced by a group of three major isoforms as a result of alternative splicing and if any three isoforms are produced (VEGFA120, VEGFA164, and VEGFA188) then this will not result in vessel defects and death of the full VEGFA knockout in mice.

Source
ActiveMax® Recombinant Mouse VEGF164, Tag Free (HPLC-verified) (VE4-M4216) is expressed from human 293 cells (HEK293). It contains AA Ala 27 - Arg 190 (Accession # AAB22253.1 ).
Predicted N-terminus: Ala 27

Molecular Characterization
This protein carries no "tag".
The protein has a calculated MW of 19.3 kDa. The protein migrates as 23-30 kDa under reducing (R) condition (SDS-PAGE) due to different glycosylation.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>95% as determined by SDS-PAGE.
>95% as determined by SEC-HPLC.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally Mannitol or Trehalose are added as protectants before lyophilization.

Reconstitution
See Certificate of Analysis for details of reconstitution instruction and specific concentration.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70^°C for 3 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1) "VEGFR2 in vascular smooth muscle cells mediates H2S-induced dilation of the rat cerebral basilar artery"
Chen, Ding, Chen et al
Microvasc Res (2022) 141, 104309
(2) "Investigation of the mechanisms of VEGF-mediated compensatory lung growth: the role of the VEGF heparin-binding domain"
Yu, Ko, Dao et al
Sci Rep (2021) 11 (1), 11827
(3) "Application of gene therapy in the treatment of superficial digital flexor tendon injury in horses"
Aimaletdinov, Mindubaeva, Khalikova et al
Open Vet J (2020) 10 (3), 261-266
Showing 1-3 of 181 papers.